Phase 4
Completed N=17
Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Source: ClinicalTrials.gov NCT02106962 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Sep 2017
Primary outcomePrimary: Clotting TIme — 6; 8 minutes
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clotting TIme |
6; 8 | — |
| SECONDARY Local Infection |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Dialysis patients with fistulas (native arterio-venous)
Exclusion Criteria
- Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.
- Active infection.
- Stenosis of fistula.
Data sourced from ClinicalTrials.gov (NCT02106962). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.